首页 工具
登录
购物车
Palbociclib

Palbociclib

产品编号 T1785   CAS 571190-30-2
别名: PD 0332991, 帕博西尼, 帕布昔利布

Palbociclib (PD 0332991) 是一种 CDK 抑制剂,抑制 CDK4 和 CDK6 (IC50=11/16 nM),具有口服活性。Palbociclib 具有抗肿瘤活性,有用于 ER 阳性和 HER2 阴性乳腺癌的研究潜力。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Palbociclib Chemical Structure
Palbociclib, CAS 571190-30-2
规格 价格/CNY 货期 数量
5 mg ¥ 398 现货
10 mg ¥ 519 现货
50 mg ¥ 754 现货
100 mg ¥ 869 现货
产品目录号及名称: Palbociclib (T1785)
点击图片重新获取验证码
选择批次  
纯度: 99.9%
纯度: 99.76%
纯度: 99.23%
纯度: 98%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.
靶点活性 CDK4:11 nM, CDK6:16 nM
体外活性 方法:恶性横纹肌样瘤细胞 G401、MP-MRT-AN (AN)、KP-MRT-RY (RY)、KP-MRT-NS (NS) 和 KP-MRT-YM (YM) 用 Palbociclib (0-1 mM) 处理 24 h,使用 WST 方法检测细胞活力。
结果:Palbociclib 以浓度依赖性的方式有效抑制 AN、RY、G401 和 NS 细胞系,IC50 分别为 0.01 μM、0.01 μM,0.06 μM 和 0.6 μM。相反,YM 细胞系对 Palbociclib 具有抗性,IC50>10 μM。[1]
方法:人乳腺癌细胞 MDA-MB-453 用 Palbociclib (0.02-10 μmol/L) 处理 24 h,使用 Flow Cytometry 方法检测细胞周期情况。
结果:Palbociclib 导致 G1 期阻滞。[2]
体内活性 方法:为检测体内抗肿瘤活性,将 Palbociclib (12.5-150 mg/kg,sodium lactate buffer (50 mmol/L, pH 4.0)) 口服给药给携带肿瘤 Colo-205 或 MDA-MB-435 的免疫缺陷小鼠,每天一次,持续十四天。
结果:Palbociclib 对多种人类肿瘤异种移植物模型显示出显著的抗肿瘤功效。对 Colo-205 肿瘤,PD 0332991 给药 14 天,可产生快速的肿瘤消退。[2]
方法:为检测体内抗肿瘤活性,将 Palbociclib (150 mg/kg,sodium lactate buffer (50 mM, pH = 4.0)) 灌胃给药给携带食道鳞状细胞癌 (ESCC) 肿瘤 EC109 或 KYSE150 的 nu/nu BALB/c 小鼠,每天一次,持续两周。
结果:Palbociclib 有效抑制 ESCC 肿瘤生长和肺转移。[3]
激酶实验 CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792-928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and Palbociclib (0.001-0.1 μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25°C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
细胞实验 Palbociclib (PD) is prepared in DMSO and stored (?80°C), and then diluted with appropriate media before use[1]. MRT cell lines, G401, MP-MRT-AN (AN), KP-MRT-RY (RY), KP-MRT-NS (NS), and KP-MRT-YM (YM) cell lines are seeded in normal growth medium into 96-well cell plates. After 24 h, the culture medium is replaced with culture medium containing Palbociclib (0.05 or 1 μM) or DMSO. Cells are cultured and treated in triplicate. Cell proliferation is determined 8 days after the treatment by WST-8 assay using a Cell Counting Kit-8.
别名 PD 0332991, 帕博西尼, 帕布昔利布
化合物与蛋白结合的复合物

T1785_2

The X-ray co-crystal structure of human CDK6 and Palbociclib.

分子量 447.53
分子式 C24H29N7O2
CAS No. 571190-30-2

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 1.3 mg/mL, Sonification is recommended.

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Katsumi Y, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun. 2011 Sep 16;413(1):62-8. 2. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. 3. Chen L, et al. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br J Pharmacol. 2017 Aug;174(15):2427-2443.

TargetMol Library Books文献引用

1. Jiang Z, Cheng L, Wu Z, et al. Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO reports. 2022: e54275 2. Qin Z, Hu H, Sun W, et al. miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells. Cancers. 2021 Feb 4;13(4):618. doi: 10.3390/cancers13040618. 3. Liu Z, Zhao Y, Kong P, et al.Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.Cancer Cell.2022 4. Wu M, Zhang X, Zhang W, et al.Paracrine secretion of IL8 by breast cancer stem cells promotes therapeutic resistance and metastasis of the bulk tumor cells.Cell Communication and Signaling.2023, 21(1): 1-17. 5. Hong J H, Yong C H, Heng H L, et al.Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.Gut.2023
OTS964 hydrochloride AMG 925 5-Iodo-indirubin-3'-monoxime Purvalanol A URMC-099 LDC4297 26-Deoxyactein CDK8/19-IN-1

相关化合物库

该产品包含在如下化合物库中:
抗癌上市药物库 药物功能重定位化合物库 抗癌临床化合物库 抗癌药物库 EMA 上市药物库 抗癌活性化合物库 抑制剂库 临床期小分子药物库 上市药物库 抗癌化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Palbociclib 571190-30-2 Cell Cycle/Checkpoint CDK PD 0332991 PD-0332991 estrogen receptor HER2 HCC inhibit 帕博西尼 Inhibitor Cyclin dependent kinase hepatocellular carcinoma cell cycle PD0332991 Breast cancer 帕布昔利布 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼